Lantern Pharma Inc. (NASDAQ: LTRN) announced that the European Medicines Agency has cleared an investigator-initiated Phase 1b/2 clinical trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE